Tumour necrosis factor enhances the therapeutic effect of mitoxantrone in human ovarian cancer xenograft
The combination of Tumour Necrosis Factor (TNF) and mitoxantrone was evaluated for potential chemotherapeutic effect against a human ovarian cancer cell line A2774 heterotransplanted in female nude mice. Both antitumour efficacy (relative survival and reduction of ascites) and toxicity (weight loss...
Gespeichert in:
| Veröffentlicht in: | Cytokine (Philadelphia, Pa.) Pa.), 1996-04, Vol.8 (4), p.330-333, Article 330 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 333 |
|---|---|
| container_issue | 4 |
| container_start_page | 330 |
| container_title | Cytokine (Philadelphia, Pa.) |
| container_volume | 8 |
| creator | Noviello, Elvira Cimoli, Guido Cosimi, Alessandro Allievi, Enrico Galletti, Piergiorgio Parodi, Silvio Russo, Patrizia |
| description | The combination of Tumour Necrosis Factor (TNF) and mitoxantrone was evaluated for potential chemotherapeutic effect against a human ovarian cancer cell line A2774 heterotransplanted in female nude mice. Both antitumour efficacy (relative survival and reduction of ascites) and toxicity (weight loss and liver toxicity) of TNF alone, mitoxantrone alone or TNF+ mitoxantrone were evaluated. A significative difference (
P< 0.002) was observed only among animals bearing tumours treated with mitoxantrone (0.012 mg/Kg) + TNF (5 × 10
5U/Kg) and controls. No cytotoxic effects were observed for this combination. These observations provide a rationale for further evaluation of TNF + mitoxantrone based regimes for the treatment of recurrent ovarian cancer. |
| doi_str_mv | 10.1006/cyto.1996.0045 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1006_cyto_1996_0045</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1043466696900459</els_id><sourcerecordid>9162224</sourcerecordid><originalsourceid>FETCH-LOGICAL-c339t-b23bc446882b3d7d57ff1e62199d3d7dcd5d052ea945b43db4b6b752ce3634c53</originalsourceid><addsrcrecordid>eNp1kE9rwyAYh2VsdF23624Dv0Ayo8Y0x1H2Dwq7dGcx-ro4mliMKe23X6Rlh8EO8vqizw9-D0L3BckLQsSjPkafF3UtckJ4eYHmBalFRghll-nOWcaFENfoZhi-CSE1q6oZmtWFoJTyOWo3Y-fHgHvQwQ9uwFbp6AOGvlW9hgHHFtIJagdjdBqDtaAj9hZ3LvqD6mPwPWDX43bsVI_9XgU3TZ3wgA_Q-6-gbLxFV1ZtB7g7zwX6fHnerN6y9cfr--ppnWnG6pg1lDWac7Fc0oaZypSVtQUIOjU0ademNKSkoGpeNpyZhjeiqUqqgQnGdckWKD_lpj5DACt3wXUqHGVBZDImkzGZjMlkbAIeTsBubDowv9_PiqZ3_idQu6ii81Nz5bb_xy5PGExl9w6CHLSDyYlxYRIojXf_oT93A47o</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Tumour necrosis factor enhances the therapeutic effect of mitoxantrone in human ovarian cancer xenograft</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Noviello, Elvira ; Cimoli, Guido ; Cosimi, Alessandro ; Allievi, Enrico ; Galletti, Piergiorgio ; Parodi, Silvio ; Russo, Patrizia</creator><creatorcontrib>Noviello, Elvira ; Cimoli, Guido ; Cosimi, Alessandro ; Allievi, Enrico ; Galletti, Piergiorgio ; Parodi, Silvio ; Russo, Patrizia</creatorcontrib><description>The combination of Tumour Necrosis Factor (TNF) and mitoxantrone was evaluated for potential chemotherapeutic effect against a human ovarian cancer cell line A2774 heterotransplanted in female nude mice. Both antitumour efficacy (relative survival and reduction of ascites) and toxicity (weight loss and liver toxicity) of TNF alone, mitoxantrone alone or TNF+ mitoxantrone were evaluated. A significative difference (
P< 0.002) was observed only among animals bearing tumours treated with mitoxantrone (0.012 mg/Kg) + TNF (5 × 10
5U/Kg) and controls. No cytotoxic effects were observed for this combination. These observations provide a rationale for further evaluation of TNF + mitoxantrone based regimes for the treatment of recurrent ovarian cancer.</description><identifier>ISSN: 1043-4666</identifier><identifier>EISSN: 1096-0023</identifier><identifier>DOI: 10.1006/cyto.1996.0045</identifier><identifier>PMID: 9162224</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Animals ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Drug Synergism ; Female ; Humans ; Lethal Dose 50 ; Mice ; Mice, Nude ; mitoxantrone ; Mitoxantrone - therapeutic use ; Nude mice ; ovarian cancer ; Ovarian Neoplasms - drug therapy ; Recombinant Proteins - therapeutic use ; therapeutic effect ; TNF ; Transplantation, Heterologous ; Tumor Cells, Cultured ; Tumor Necrosis Factor-alpha - pharmacology</subject><ispartof>Cytokine (Philadelphia, Pa.), 1996-04, Vol.8 (4), p.330-333, Article 330</ispartof><rights>1996 Academic Press</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c339t-b23bc446882b3d7d57ff1e62199d3d7dcd5d052ea945b43db4b6b752ce3634c53</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1043466696900459$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9162224$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Noviello, Elvira</creatorcontrib><creatorcontrib>Cimoli, Guido</creatorcontrib><creatorcontrib>Cosimi, Alessandro</creatorcontrib><creatorcontrib>Allievi, Enrico</creatorcontrib><creatorcontrib>Galletti, Piergiorgio</creatorcontrib><creatorcontrib>Parodi, Silvio</creatorcontrib><creatorcontrib>Russo, Patrizia</creatorcontrib><title>Tumour necrosis factor enhances the therapeutic effect of mitoxantrone in human ovarian cancer xenograft</title><title>Cytokine (Philadelphia, Pa.)</title><addtitle>Cytokine</addtitle><description>The combination of Tumour Necrosis Factor (TNF) and mitoxantrone was evaluated for potential chemotherapeutic effect against a human ovarian cancer cell line A2774 heterotransplanted in female nude mice. Both antitumour efficacy (relative survival and reduction of ascites) and toxicity (weight loss and liver toxicity) of TNF alone, mitoxantrone alone or TNF+ mitoxantrone were evaluated. A significative difference (
P< 0.002) was observed only among animals bearing tumours treated with mitoxantrone (0.012 mg/Kg) + TNF (5 × 10
5U/Kg) and controls. No cytotoxic effects were observed for this combination. These observations provide a rationale for further evaluation of TNF + mitoxantrone based regimes for the treatment of recurrent ovarian cancer.</description><subject>Animals</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Drug Synergism</subject><subject>Female</subject><subject>Humans</subject><subject>Lethal Dose 50</subject><subject>Mice</subject><subject>Mice, Nude</subject><subject>mitoxantrone</subject><subject>Mitoxantrone - therapeutic use</subject><subject>Nude mice</subject><subject>ovarian cancer</subject><subject>Ovarian Neoplasms - drug therapy</subject><subject>Recombinant Proteins - therapeutic use</subject><subject>therapeutic effect</subject><subject>TNF</subject><subject>Transplantation, Heterologous</subject><subject>Tumor Cells, Cultured</subject><subject>Tumor Necrosis Factor-alpha - pharmacology</subject><issn>1043-4666</issn><issn>1096-0023</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kE9rwyAYh2VsdF23624Dv0Ayo8Y0x1H2Dwq7dGcx-ro4mliMKe23X6Rlh8EO8vqizw9-D0L3BckLQsSjPkafF3UtckJ4eYHmBalFRghll-nOWcaFENfoZhi-CSE1q6oZmtWFoJTyOWo3Y-fHgHvQwQ9uwFbp6AOGvlW9hgHHFtIJagdjdBqDtaAj9hZ3LvqD6mPwPWDX43bsVI_9XgU3TZ3wgA_Q-6-gbLxFV1ZtB7g7zwX6fHnerN6y9cfr--ppnWnG6pg1lDWac7Fc0oaZypSVtQUIOjU0ademNKSkoGpeNpyZhjeiqUqqgQnGdckWKD_lpj5DACt3wXUqHGVBZDImkzGZjMlkbAIeTsBubDowv9_PiqZ3_idQu6ii81Nz5bb_xy5PGExl9w6CHLSDyYlxYRIojXf_oT93A47o</recordid><startdate>19960401</startdate><enddate>19960401</enddate><creator>Noviello, Elvira</creator><creator>Cimoli, Guido</creator><creator>Cosimi, Alessandro</creator><creator>Allievi, Enrico</creator><creator>Galletti, Piergiorgio</creator><creator>Parodi, Silvio</creator><creator>Russo, Patrizia</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>19960401</creationdate><title>Tumour necrosis factor enhances the therapeutic effect of mitoxantrone in human ovarian cancer xenograft</title><author>Noviello, Elvira ; Cimoli, Guido ; Cosimi, Alessandro ; Allievi, Enrico ; Galletti, Piergiorgio ; Parodi, Silvio ; Russo, Patrizia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c339t-b23bc446882b3d7d57ff1e62199d3d7dcd5d052ea945b43db4b6b752ce3634c53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>Animals</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Drug Synergism</topic><topic>Female</topic><topic>Humans</topic><topic>Lethal Dose 50</topic><topic>Mice</topic><topic>Mice, Nude</topic><topic>mitoxantrone</topic><topic>Mitoxantrone - therapeutic use</topic><topic>Nude mice</topic><topic>ovarian cancer</topic><topic>Ovarian Neoplasms - drug therapy</topic><topic>Recombinant Proteins - therapeutic use</topic><topic>therapeutic effect</topic><topic>TNF</topic><topic>Transplantation, Heterologous</topic><topic>Tumor Cells, Cultured</topic><topic>Tumor Necrosis Factor-alpha - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Noviello, Elvira</creatorcontrib><creatorcontrib>Cimoli, Guido</creatorcontrib><creatorcontrib>Cosimi, Alessandro</creatorcontrib><creatorcontrib>Allievi, Enrico</creatorcontrib><creatorcontrib>Galletti, Piergiorgio</creatorcontrib><creatorcontrib>Parodi, Silvio</creatorcontrib><creatorcontrib>Russo, Patrizia</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Cytokine (Philadelphia, Pa.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Noviello, Elvira</au><au>Cimoli, Guido</au><au>Cosimi, Alessandro</au><au>Allievi, Enrico</au><au>Galletti, Piergiorgio</au><au>Parodi, Silvio</au><au>Russo, Patrizia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tumour necrosis factor enhances the therapeutic effect of mitoxantrone in human ovarian cancer xenograft</atitle><jtitle>Cytokine (Philadelphia, Pa.)</jtitle><addtitle>Cytokine</addtitle><date>1996-04-01</date><risdate>1996</risdate><volume>8</volume><issue>4</issue><spage>330</spage><epage>333</epage><pages>330-333</pages><artnum>330</artnum><issn>1043-4666</issn><eissn>1096-0023</eissn><abstract>The combination of Tumour Necrosis Factor (TNF) and mitoxantrone was evaluated for potential chemotherapeutic effect against a human ovarian cancer cell line A2774 heterotransplanted in female nude mice. Both antitumour efficacy (relative survival and reduction of ascites) and toxicity (weight loss and liver toxicity) of TNF alone, mitoxantrone alone or TNF+ mitoxantrone were evaluated. A significative difference (
P< 0.002) was observed only among animals bearing tumours treated with mitoxantrone (0.012 mg/Kg) + TNF (5 × 10
5U/Kg) and controls. No cytotoxic effects were observed for this combination. These observations provide a rationale for further evaluation of TNF + mitoxantrone based regimes for the treatment of recurrent ovarian cancer.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>9162224</pmid><doi>10.1006/cyto.1996.0045</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1043-4666 |
| ispartof | Cytokine (Philadelphia, Pa.), 1996-04, Vol.8 (4), p.330-333, Article 330 |
| issn | 1043-4666 1096-0023 |
| language | eng |
| recordid | cdi_crossref_primary_10_1006_cyto_1996_0045 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Animals Antineoplastic Combined Chemotherapy Protocols - therapeutic use Drug Synergism Female Humans Lethal Dose 50 Mice Mice, Nude mitoxantrone Mitoxantrone - therapeutic use Nude mice ovarian cancer Ovarian Neoplasms - drug therapy Recombinant Proteins - therapeutic use therapeutic effect TNF Transplantation, Heterologous Tumor Cells, Cultured Tumor Necrosis Factor-alpha - pharmacology |
| title | Tumour necrosis factor enhances the therapeutic effect of mitoxantrone in human ovarian cancer xenograft |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T06%3A22%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tumour%20necrosis%20factor%20enhances%20the%20therapeutic%20effect%20of%20mitoxantrone%20in%20human%20ovarian%20cancer%20xenograft&rft.jtitle=Cytokine%20(Philadelphia,%20Pa.)&rft.au=Noviello,%20Elvira&rft.date=1996-04-01&rft.volume=8&rft.issue=4&rft.spage=330&rft.epage=333&rft.pages=330-333&rft.artnum=330&rft.issn=1043-4666&rft.eissn=1096-0023&rft_id=info:doi/10.1006/cyto.1996.0045&rft_dat=%3Cpubmed_cross%3E9162224%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/9162224&rft_els_id=S1043466696900459&rfr_iscdi=true |